Logo
x

Search category

Subscribe Now

Advanced Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval as 1L Treatment of Advanced Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval as 1L Treatment of Advanced Renal Cell Carci...

  • August 12, 2021
PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced Renal Cell Carcinoma

PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced...

  • May 11, 2021
Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal Cell Carcinoma and Endometrial Carcinoma

Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal C...

  • May 7, 2021
AVEO Oncology's Fotivda (tivozanib) Receives the US FDA's Approval for the Treatment of R/R Advanced Renal Cell Carcinoma

AVEO Oncology's Fotivda (tivozanib) Receives the US FDA's Approval for the Treatment of R/R Advanced Renal Cell Carcinoma

  • March 10, 2021
Exelixis Cabometyx (cabozantinib) + Opdivo (nivolumab) Receives US FDA's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Exelixis Cabometyx (cabozantinib) + Opdivo (nivolumab) Receives US FDA's Approval as a 1L Treatment for Patients with Advanced Ren...

  • January 25, 2021
Pfizer's Bavencio (avelumab) + Axitinib Dual Regimen Receive EC's Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Pfizer's Bavencio (avelumab) + Axitinib Dual Regimen Receive EC's Approval as 1L Treatment for Advanced Renal Cell Carcinoma

  • October 29, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.